Diet ( DrugBank: - )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	71
240	Phenylketonuria	37
299	Cystic fibrosis	49

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04276740 (ClinicalTrials.gov)	November 1, 2021	12/2/2020	MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis	Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis (MARVEL): A Randomised Placebo-controlled Trial on Oral MitoQ in Moderate UC	Ulcerative Colitis Flare	Dietary Supplement: MitoQ;Other: Placebo	University of Edinburgh	JP Moulton Charitable Foundation;MitoQ	Not yet recruiting	18 Years	N/A	All	206	Phase 2	NULL
2	NCT04933162 (ClinicalTrials.gov)	August 3, 2021	15/6/2021	UC Cohort - The Influence of Diet on Gut Microbiotas	UC Cohort - The Influence of Diet on Host Physiology and Disease Across Diverse Human Gut Microbiotas	Ulcerative Colitis	Dietary Supplement: High Protein and Low Fiber Diet;Dietary Supplement: Low Protein and High Fiber Diet	Mayo Clinic	NULL	Recruiting	18 Years	N/A	All	70	N/A	United States
3	NCT04898530 (ClinicalTrials.gov)	May 15, 2021	13/5/2021	Diet Patterns in IBD in Central Texas	A Cross-sectional Assessment of Diet in Patients With IBD in Central Texas	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Other: NO INTERVENTION	University of Texas at Austin	NULL	Recruiting	18 Years	N/A	All	500		United States
4	NCT04749576 (ClinicalTrials.gov)	December 15, 2020	9/12/2020	Saffron as Anti Inflammatory Agent In Patients With Inflammatory Bowel Disease	Efficacy of Nutritional Saffron Supplement As An Anti Inflammatory Agent In Patients With Inflammatory Bowel Disease	Ulcerative Colitis	Dietary Supplement: saffron supplement for IBD	Howard University	NULL	Recruiting	18 Years	80 Years	All	100	N/A	United States
5	NCT04505410 (ClinicalTrials.gov)	November 18, 2020	5/8/2020	Xeljanz and Healthy Diet	A Randomized Control Study to Examine the Influence of a Healthy Diet on Moderate to Severe Ulcerative Colitis Patients Undergoing Tofacitinib (Xeljanz) Induction	Ulcerative Colitis	Drug: Tofacitinib;Other: Fast Mimicking Diet	University of Miami	Pfizer	Recruiting	18 Years	N/A	All	76	Phase 3	United States
6	NCT04331639 (ClinicalTrials.gov)	November 1, 2020	23/3/2020	High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy	Implementation of High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Infliximab or Vedolizumab	Inflammatory Bowel Disease;Crohn Disease;Ulcerative Colitis;Vitamin D Deficiency	Dietary Supplement: vitamin D3	Boston Children's Hospital	NULL	Recruiting	5 Years	25 Years	All	50	Phase 2	United States
7	EUCTR2018-005086-39-BG (EUCTR)	27/10/2020	25/06/2020	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis	Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors. MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: BT-11 500 mg Product Code: BT-11 INN or Proposed INN: to be requested Other descriptive name: BT-11 Product Name: BT-11 1000mg Product Code: BT-11 INN or Proposed INN: to be requested Other descriptive name: BT-11	Landos Biopharma Inc.	NULL	Not Recruiting			Female: yes Male: yes	195	Phase 2	United States;Serbia;Belarus;Hungary;Poland;Ukraine;Croatia;Russian Federation;Georgia;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
8	JPRN-UMIN000041972	2020/10/01	01/10/2020	Clinical trial on the effects of dietary intake of sulforaphane-rich broccoli sprouts on severity of ulcerative colitis.	Clinical trial on the effects of dietary intake of sulforaphane-rich broccoli sprouts on severity of ulcerative colitis. - BS-UC-2020	ulcerative colitis	Broccoli Sprouts (20 g/day, 8 weeks) Alfalfa Sprouts (20 g/day, 8 weeks)	University of Tsukuba	NULL	Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
9	NCT04225819 (ClinicalTrials.gov)	October 1, 2020	3/1/2020	Adjunctive Treatment With Vitamin D3 in Patients With Active IBD	Adjunctive Treatment With Vitamin D3 in Patients With Active IBD (ACTIVATED): A Randomized, Double-blind, Placebo-controlled Trial	IBD;Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Vitamin D3 Deficiency	Dietary Supplement: Vitamin D3;Other: Placebo	Massachusetts General Hospital	NULL	Recruiting	18 Years	N/A	All	100	N/A	United States
10	NCT04223518 (ClinicalTrials.gov)	September 20, 2020	6/1/2020	Serum Bovine Immunoglobulin (SBI) in Children and Young Adults With Inflammatory Bowel Disease (IBD)	Safety, Tolerability, and Nutritional Impact of Serum Bovine Immunoglobulin (SBI) in Children and Young Adults With Inflammatory Bowel Disease	Inflammatory Bowel Diseases;Ulcerative Colitis;Crohn Disease	Dietary Supplement: Serum bovine immunoglobulin;Dietary Supplement: Placebo	Monisha Hitesh Shah	NULL	Recruiting	6 Years	30 Years	All	43	Early Phase 1	United States
11	NCT04188990 (ClinicalTrials.gov)	June 15, 2020	2/12/2019	Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition	Evaluation of the Effectiveness and Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition	Pancreatitis, Acute;Crohn Disease;Ulcerative Colitis;Inflammatory Bowel Diseases;Pancreatic Cancer;Esophagus Cancer;Gastric Cancer;Colorectal Cancer	Dietary Supplement: Nutritional dietary intervention;Dietary Supplement: By demand;Dietary Supplement: Usual current care	Hospital Galdakao-Usansolo	NULL	Active, not recruiting	18 Years	N/A	All	900	N/A	Spain
12	NCT03980405 (ClinicalTrials.gov)	April 1, 2020	5/6/2019	Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis	Combination Therapy With Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative Colitis: A Single Blinded, International Randomized Controlled Trial	Ulcerative Colitis	Dietary Supplement: Group 1- Control Diet;Dietary Supplement: Group 2- UCD Diet	Prof. Arie Levine	NULL	Recruiting	10 Years	19 Years	All	62	N/A	Israel
13	NCT04332328 (ClinicalTrials.gov)	April 1, 2020	31/3/2020	Study of Demographic and Dietary Profile in Patients With Ulcerative Colitis in Upper Egypt	Study of Demographic and Dietary Profile in Patients With Ulcerative Colitis in Upper Egypt	Diet in Ulcerative Colitis Patients	Dietary Supplement: Diet	Assiut University	NULL	Not yet recruiting	N/A	N/A	All	50		NULL
14	NCT02277223 (ClinicalTrials.gov)	March 1, 2020	25/10/2014	Curcumin in Pediatric Ulcerative Colitis	Curcumin for Induction and Maintenance Therapy in Pediatric Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Curcumin;Drug: Placebo	Schneider Children's Medical Center, Israel	NULL	Withdrawn	6 Years	18 Years	All	0	Phase 3	Israel
15	EUCTR2019-003220-21-GB (EUCTR)	26/02/2020	12/12/2019	Management of diarrhoea in ulcerative colitis: multi-arm multi stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE.	Management of diarrhoea in ulcerative colitis: multi-arm multi-stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE. - MODULATE	Diarrhoea in patients with stable ulcerative colitis. MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 MedDRA version: 20.1;Classification code 10033007;Term: Other ulcerative colitis;Classification code 10066557;Term: Chronic diarrhoea;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Amitriptyline Product Name: Amitriptyline INN or Proposed INN: Amitriptyline hydrochloride Product Name: Ondansetron INN or Proposed INN: Ondansetron hydrochloride dihydrate Product Name: Loperamide INN or Proposed INN: loperamide hydrochloride	University of Leeds	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	491	Phase 2;Phase 3	United Kingdom
16	NCT04241029 (ClinicalTrials.gov)	February 25, 2020	17/1/2020	Boosting Biologics in UC	Boosting Biologics in Ulcerative Colitis	Ulcerative Colitis;Inflammatory Bowel Diseases	Dietary Supplement: IDOFORM®Travel	Oslo University Hospital	Helse Sor-Ost	Recruiting	18 Years	75 Years	All	20	Phase 1	Norway
17	NCT03998488 (ClinicalTrials.gov)	January 31, 2020	24/6/2019	Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis	A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative Colitis	Ulcerative Colitis;Inflammatory Bowel Diseases	Drug: Fecal Microbiota Transplantation;Dietary Supplement: Psyllium Husk Powder	Weill Medical College of Cornell University	Crohn's and Colitis Foundation	Recruiting	18 Years	89 Years	All	135	Phase 2	United States
18	EUCTR2018-005086-39-HR (EUCTR)	16/12/2019	17/01/2020	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis	Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors. MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: BT-11 500 mg Product Code: BT-11 INN or Proposed INN: to be requested Other descriptive name: BT-11 Product Name: BT-11 1000mg Product Code: BT-11 INN or Proposed INN: to be requested Other descriptive name: BT-11	Landos Biopharma Inc.	NULL	Not Recruiting			Female: yes Male: yes	195	Phase 2	Belarus;Serbia;United States;Ukraine;Russian Federation;Hungary;Canada;Poland;Croatia;Bulgaria;Georgia;Moldova, Republic of;Bosnia and Herzegovina
19	EUCTR2018-005086-39-HU (EUCTR)	28/10/2019	08/04/2019	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis	Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors. MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: BT-11 INN or Proposed INN: to be requested Product Code: BT-11 INN or Proposed INN: to be requested	Landos Biopharma Inc.	NULL	Not Recruiting			Female: yes Male: yes	195	Phase 2	United States;Serbia;Belarus;Hungary;Poland;Ukraine;Croatia;Bulgaria;Russian Federation;Georgia;Moldova, Republic of;Bosnia and Herzegovina
20	EUCTR2018-005086-39-PL (EUCTR)	07/10/2019	06/05/2019	A Study to Evaluate Efficacy and Safety of BT-11 product oral tablets in Mild to Moderate Ulcerative Colitis	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis	Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors. MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: BT-11 500 mg Product Code: BT-11 INN or Proposed INN: to be requested Other descriptive name: BT-11 Product Name: BT-11 1000mg Product Code: BT-11 INN or Proposed INN: to be requested Other descriptive name: BT-11	Landos Biopharma Inc.	NULL	Not Recruiting			Female: yes Male: yes	195	Phase 2	United States;Serbia;Belarus;Hungary;Poland;Ukraine;Croatia;Bulgaria;Russian Federation;Georgia;Moldova, Republic of;Bosnia and Herzegovina
21	NCT04006977 (ClinicalTrials.gov)	October 2019	1/7/2019	Multistrain Probiotics Reduces UC Depression and Anxiety Scores	Multistrain Probiotic Product (De Simone Formulation) Reduces Depression and Anxiety Scores: a Randomized Pilot Study in Patients With Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: a multistrain probiotic product (DSF);Dietary Supplement: Placebo	Xijing Hospital of Digestive Diseases	MENDES SA	Not yet recruiting	18 Years	65 Years	All	60	N/A	China
22	NCT04102852 (ClinicalTrials.gov)	September 30, 2019	17/9/2019	Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients	The Role of Lactobacillus Rhamnosus GG (ATCC 53103) in the Modulation of the Inflammatory Process in the Mucosa of Ulcerative Colitis (UC) Patients With Mild-moderate Clinical Activity	Ulcerative Colitis Chronic Mild;Ulcerative Colitis Chronic Moderate	Dietary Supplement: Lactobacillus rhamnosus GG ATCC 53103	San Giovanni Addolorata Hospital	Onlus S. Andrea	Recruiting	18 Years	65 Years	All	80	Phase 1/Phase 2	Italy
23	NCT03847467 (ClinicalTrials.gov)	September 20, 2019	12/2/2019	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in Pediatric and Young Adult IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Drug: 2'-Fucosyllactose;Other: Placebo	Children's Hospital Medical Center, Cincinnati	Broad Institute;University of Cincinnati;Connecticut Children's Medical Center	Recruiting	11 Years	25 Years	All	216	Phase 1/Phase 2	United States
24	NCT03941418 (ClinicalTrials.gov)	June 1, 2019	5/5/2019	Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn Disease	Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn Disease	Ulcerative Colitis;Crohn Disease	Dietary Supplement: Boulardii;Dietary Supplement: Placebo	University Clinic Dr Dragisa Misovic-Dedinje	University Clinic Zvezdara	Not yet recruiting	18 Years	80 Years	All	150	N/A	NULL
25	NCT03720002 (ClinicalTrials.gov)	May 29, 2019	21/10/2018	HF2 Therapy in the Treatment of Active Ulcerative Colitis	HF2 Therapy in the Treatment of Active Ulcerative Colitis:	Ulcerative Colitis	Dietary Supplement: HF2	Sheba Medical Center	NULL	Recruiting	18 Years	70 Years	All	34	Phase 1/Phase 2	Israel
26	NCT02201758 (ClinicalTrials.gov)	December 2018	18/7/2014	Flaxseed Lignan-Enriched Complex (FLC) for the Treatment of Patients With Ulcerative Colitis (UC): A Pilot Assessment	Flaxseed Lignan-enriched Complex (FLC) for the Treatment of Patients With Mild to Moderately Severe Ulcerative Colitis (UC): A Pilot Assessment.	Ulcerative Colitis	Dietary Supplement: Flaxseed lignan-enriched complex (FLC);Other: Placebo	University of Saskatchewan	Royal University Hospital Foundation	Unknown status	18 Years	N/A	All	56	Phase 2	Canada
27	NCT02469220 (ClinicalTrials.gov)	July 1, 2018	8/6/2015	Diet Treatment of Patients With Ulcerative Colitis in Remission	Diet Treatment of Patients With Ulcerative Colitis in Remission	Ulcerative Colitis	Dietary Supplement: Low FODMAP;Dietary Supplement: Standardized FODMAP	Vendsyssel Hospital	NULL	Active, not recruiting	18 Years	70 Years	All	19	N/A	Denmark
28	NCT04329481 (ClinicalTrials.gov)	June 12, 2018	29/3/2020	The Effect of Mycobiome Supplementation on Gastrointestinal Symptoms in IBD Patients	The Effect of Mycobiome Supplementation on Gastrointestinal Symptoms in IBD Patients	Ulcerative Colitis;Crohn Disease;Inflammatory Bowel Diseases	Dietary Supplement: Mycodigest supplement	Tel-Aviv Sourasky Medical Center	NULL	Recruiting	18 Years	70 Years	All	100	N/A	Israel
29	NCT03594708 (ClinicalTrials.gov)	April 30, 2018	19/1/2018	Immunonutrition in Ulcerative Colitis	Impact of Immunonutrition Supplementation Combining Fermentable Fiber, Omega-3 Fatty Acids, Vitamin D, Vitamin E, and Zinc on Intestinal Inflammation, Gut Microbial Activity, and Severity of Symptoms in Ulcerative Colitis Patients	Ulcerative Colitis	Dietary Supplement: Nutrition supplement;Dietary Supplement: Placebo supplement	Baptist Memorial Health Care Corporation	NULL	Unknown status	18 Years	N/A	All	30	N/A	United States
30	NCT03444311 (ClinicalTrials.gov)	March 8, 2018	8/2/2018	Combined Nutritional Therapies for the Treatment of Ulcerative Colitis	Development of Combined Nutritional Therapies for the Treatment of Ulcerative Colitis Through the Increase of the Biodiversity of the Microbiota.	Colitis, Ulcerative	Dietary Supplement: A: 1 dosis;Dietary Supplement: B: 2 dosis	AB Biotics, SA	NULL	Terminated	18 Years	65 Years	All	12	N/A	Spain
31	NCT03309865 (ClinicalTrials.gov)	December 25, 2017	7/10/2017	Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.	A Pilot Study Evaluating the Synergistic Effect of Vedolizumab in Conjunction With Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis.	Ulcerative Colitis;Dietary Modification	Dietary Supplement: semi-vegetarian diet;Drug: Vedolizumab Injection	Mayo Clinic	NULL	Withdrawn	18 Years	N/A	All	0	Early Phase 1	United States
32	NCT03266484 (ClinicalTrials.gov)	November 13, 2017	25/8/2017	Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease	Effect of Dietary Therapy With a Probiotic Mixture on the Gut Microbiome and Fatigue Symptoms in Patients With Quiescent Inflammatory Bowel Disease - A Clinical Trial	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Dietary Supplement: Probiotic Mixture;Dietary Supplement: Placebo	Massachusetts General Hospital	Winclove Bio Industries BV	Recruiting	18 Years	75 Years	All	100	N/A	United States
33	NCT03122613 (ClinicalTrials.gov)	June 19, 2017	7/4/2017	Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis	A Double-blind, Randomized, Placebo-Controlled Trial of Curcumin Versus Placebo for Prevention of Relapse in Patients With Ulcerative Colitis	Ulcerative Colitis in Remission	Dietary Supplement: Curcumin;Drug: Placebo	Chinese University of Hong Kong	NULL	Recruiting	18 Years	N/A	All	172	N/A	Hong Kong
34	NCT03415711 (ClinicalTrials.gov)	April 28, 2017	5/1/2018	PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis	A Double-blind, Randomized, Placebo-controlled, Single-center, Dose-finding, Pilot Study Evaluating the Efficacy of VSL#3® in the Maintenance of Clinical and Endoscopic Remission of Mild-to-moderate UC	Ulcerative Colitis	Dietary Supplement: VSL#3®;Drug: Mesalamine;Drug: Placebo	VSL Pharmaceuticals	Actial Farmaceutica S.r.l.	Terminated	18 Years	85 Years	All	14	N/A	Italy
35	NCT03000101 (ClinicalTrials.gov)	January 19, 2017	19/12/2016	Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease	New Insight and Knowledge on Anti-inflammatory Effectiveness of Dietary Phenolics (NIKE)	Crohn's Disease;Ulcerative Colitis	Other: 100% pomegranate juice;Other: placebo beverage	IRCCS Azienda Ospedaliero-Universitaria di Bologna	University of Bologna;Conserve Italia;GAT Foods	Active, not recruiting	18 Years	80 Years	All	18	N/A	Italy
36	NCT03798210 (ClinicalTrials.gov)	January 1, 2017	7/1/2019	Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis	The Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative Colitis	Ulcerative Colitis Flare	Dietary Supplement: Lactobacillus reuteri;Dietary Supplement: Placebo	Uppsala University	NULL	Recruiting	18 Years	80 Years	All	40	Phase 2	Sweden
37	NCT03136419 (ClinicalTrials.gov)	October 31, 2016	5/4/2017	Microbiota and Immune microEnvironment in Pouchitis	Microbiota and Immune microEnvironment in Pouchitis: Randomized Controlled Trial Oral Administration of Lactobacillus Casei DG After Ileostomy Closure in Ileal Pouch Mucosa	Pouchitis;Ulcerative Colitis;Ileal Pouch	Dietary Supplement: Lactobacillus casei DG;Dietary Supplement: Placebo	University of Padova	NULL	Recruiting	18 Years	100 Years	All	32	N/A	Italy
38	NCT02825914 (ClinicalTrials.gov)	September 1, 2016	30/6/2016	CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)	CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)	Colitis, Ulcerative;Inflammatory Bowel Diseases	Dietary Supplement: Casein glycomacropeptide (CGMP);Dietary Supplement: Placebo	University of Aarhus	NULL	Completed	18 Years	N/A	All	80	N/A	Denmark
39	NCT02865707 (ClinicalTrials.gov)	August 2016	12/7/2016	Ulcerative Colitis Relapse Prevention by Prebiotics	Prevention of Ulcerative Colitis by Prebiotics: Efficacy and Protective Mechanisms	Ulcerative Colitis	Dietary Supplement: Synergy-1;Dietary Supplement: Maltodextrin	University of Alberta	University of British Columbia	Recruiting	18 Years	75 Years	All	100	N/A	Canada
40	NCT02683733 (ClinicalTrials.gov)	February 2016	10/2/2016	Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis	The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Bio-enhanced Curcumin Soft Gelatin Capsule;Drug: 5-Aminosalicylic acid	Asian Institute of Gastroenterology, India	NULL	Recruiting	18 Years	70 Years	Both	50	Phase 3	India
41	NCT02683759 (ClinicalTrials.gov)	February 2016	10/2/2016	Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis	The Efficacy and Tolerability of Bio-Enhanced Curcumin in Maintaining Remission in Patients With Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Bio-enhanced Curcumin Soft Gelatin Capsule;Drug: 5-Aminosalicyclic acid	Asian Institute of Gastroenterology, India	NULL	Recruiting	18 Years	70 Years	Both	50	Phase 3	India
42	NCT02345733 (ClinicalTrials.gov)	September 2015	19/1/2015	Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis	Use of a Novel Diet (UC DIET) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study	Ulcerative Colitis (UC)	Other: Ulcerative Colitis Diet;Drug: Antibiotic cocktail	Prof. Arie Levine	NULL	Recruiting	8 Years	19 Years	All	20	Phase 4	United States;Canada;Israel
43	NCT02084550 (ClinicalTrials.gov)	September 2015	5/3/2014	Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis	Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis: a Randomized, Assessor-blinded, Placebo-controlled Trial	Ulcerative Colitis	Dietary Supplement: Vaminolac;Other: Saline	Aarhus University Hospital	NULL	Active, not recruiting	18 Years	50 Years	All	8	N/A	Denmark
44	NCT02361957 (ClinicalTrials.gov)	November 2014	15/1/2015	The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients	The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients	Ulcerative Colitis	Dietary Supplement: Ecologic 825;Dietary Supplement: Placebo	Wageningen University	NULL	Suspended	18 Years	65 Years	Both	40	N/A	Netherlands
45	NCT02217722 (ClinicalTrials.gov)	October 2014	20/7/2014	Use of the Ulcerative Colitis Diet for Induction of Remission	An Open Label Non Randomized Pilot Study: Use of the Ulcerative Colitis Diet for Induction of Remission.	Ulcerative Colitis (UC)	Other: Ulcerative Colitis Diet;Drug: Antibiotic cocktail	Prof. Arie Levine	NULL	Terminated	5 Years	18 Years	Both	9	N/A	Israel
46	NCT02179372 (ClinicalTrials.gov)	June 2014	29/6/2014	Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases	Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases	Ulcerative Colitis;Crohn's Disease	Dietary Supplement: Eicosapentaenoic acid;Dietary Supplement: Medium chain fatty acid (placebo)	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi	NULL	Completed	18 Years	80 Years	Both	60	N/A	Italy
47	NCT01765439 (ClinicalTrials.gov)	February 2014	7/1/2013	The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	The Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	Crohn Disease;Ulcerative Colitis	Dietary Supplement: VSL#3 (Original De Simone formulation)	Charles University, Czech Republic	Iscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La Sapienza	Active, not recruiting	N/A	N/A	All	79	N/A	Czechia;Czech Republic
48	NCT02069561 (ClinicalTrials.gov)	January 2014	19/2/2014	Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer	Effects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel Disease	Ulcerative Colitis	Dietary Supplement: Eicosapentaenoic Acid	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi	NULL	Completed	18 Years	70 Years	Both	25	N/A	Italy
49	NCT01771224 (ClinicalTrials.gov)	January 2013	16/1/2013	Effect of FAn-7 in UC Activity	Effect of Palmitoleic Acid (FAn-7) on Expression of HNF4? and Ulcerative Colitis (UC) Activity	Inflammatory Bowel Disease;Ulcerative Colitis	Dietary Supplement: Palmitoleic acid	National Institute of Medical Sciences and Nutrition, Salvador Zubiran	NULL	Recruiting	18 Years	59 Years	Both	20	Phase 0	Mexico
50	NCT01078935 (ClinicalTrials.gov)	December 2012	1/3/2010	The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation	The Effect of Probiotics on Bowel Disease	Crohn's Disease;Ulcerative Colitis	Dietary Supplement: probiotics;Dietary Supplement: placebo	The Baruch Padeh Medical Center, Poriya	Ministry of Health, Israel	Not yet recruiting	18 Years	80 Years	Both	100	Phase 4	NULL
51	NCT01783119 (ClinicalTrials.gov)	August 2012	31/1/2013	Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis	Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Aloe Barbadensis Miller;Dietary Supplement: placebo water	National Institute of Medical Sciences and Nutrition, Salvador Zubiran	NULL	Recruiting	18 Years	59 Years	Both	60	Phase 0	Mexico
52	NCT01877577 (ClinicalTrials.gov)	April 2012	11/6/2013	Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D	Supplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.	Crohn's Disease (CD);Ulcerative Colitis (UC)	Dietary Supplement: Vitamin D3	University of California, San Francisco	NULL	Completed	18 Years	N/A	Both	30	N/A	United States
53	NCT01496053 (ClinicalTrials.gov)	December 2011	15/12/2011	Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)	Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study	Ulcerative Colitis;Crohn's Disease;Inflammatory Bowel Disease	Dietary Supplement: AndoSan;Dietary Supplement: Sugar Extract	Oslo University Hospital	ImmunoPharma AS	Completed	18 Years	60 Years	All	100	Phase 2/Phase 3	Norway
54	NCT01320436 (ClinicalTrials.gov)	July 2011	21/3/2011	Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis	Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients	Ulcerative Colitis	Dietary Supplement: Curcumin;Drug: 5-aminosalicylic acid	Sheba Medical Center	NULL	Completed	18 Years	70 Years	Both	50	Phase 3	Israel
55	NCT01772615 (ClinicalTrials.gov)	May 2011	17/1/2013	Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle	Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle	Ulcerative Colitis	Drug: Ciprofloxacin;Dietary Supplement: E. coli Nissle	Hvidovre University Hospital	NULL	Completed	18 Years	N/A	Both	100	Phase 4	Denmark
56	NCT01065571 (ClinicalTrials.gov)	January 2010	4/2/2010	Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity	Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity	Ulcerative Colitis	Dietary Supplement: carrageenan;Other: dietary intervention with no-carrageenan diet	University of Illinois at Chicago	The Broad Foundation;University of Chicago	Completed	18 Years	N/A	All	15	N/A	United States
57	NCT00793130 (ClinicalTrials.gov)	November 2008	16/11/2008	The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label	The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label	Ulcerative Colitis	Dietary Supplement: Coltect	Tel-Aviv Sourasky Medical Center	NULL	Recruiting	18 Years	75 Years	Both	30	N/A	Israel
58	NCT00751933 (ClinicalTrials.gov)	October 2008	11/9/2008	Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis	A Controlled Study of Salmonella Ty21a and Cholera/ ETEC-vaccine and the Role of Oats in Daily Diet as a New Treatment in Patients With Mild or Moderate Ulcerative Colitis.	Ulcerative Colitis	Biological: Vaccine Vivotif + Vaccine Dukoral + oats;Biological: Vaccine Vivotif + Vaccine Dukoral;Dietary Supplement: Oats;Other: Placebo	Haukeland University Hospital	Helse Vest	Terminated	18 Years	80 Years	All	3	Phase 2	Norway
59	ChiCTR-TRC-08000145	2008-09-01	2008-08-25	The study of the treatment and rehabilitation of ulcerative colitis	The study of the treatment and rehabilitation of ulcerative colitis	Ulcerative Colitis	1:5-ASA and low residue diet;2:5-ASA and EN;3:5-ASA and low residue diet and microecology prepar;4:5-ASA and low residue diet ang Gln;5:5-ASA and EN and Gln and microecology preparation;	Friendship Hospital of Capital Medical University	NULL	Completed	18	70	Both	1:60;2:60;3:60;4:60;5:60;	I (Phase 1 study)	China
60	NCT00621257 (ClinicalTrials.gov)	January 2008	11/2/2008	Vitamin D Levels in Children With IBD	Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Dietary Supplement: ergocalciferol;Dietary Supplement: Cholecalciferol	Boston Children’s Hospital	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Crohn's and Colitis Foundation;NASPGHAN Foundation	Terminated	5 Years	21 Years	All	134	N/A	United States
61	NCT00578799 (ClinicalTrials.gov)	December 2007	18/12/2007	Effects of Probiotics in Patients With Ulcerative Colitis	Effects of Probiotics in Patients With Ulcerative Colitis.	Ulcerative Colitis	Dietary Supplement: Kyo-Dophilus;Dietary Supplement: placebo	University of California, Irvine	Wakunaga Pharmaceutical Co., Ltd.	Withdrawn	18 Years	65 Years	All	0	Phase 1	United States
62	NCT02093767 (ClinicalTrials.gov)	August 2007	19/3/2014	Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative Colitis	Open-Label Trial of a Prebiotic Preparation Containing Inulin and Oligofructose (Synergy-1) for the Treatment of Mild to Moderate Acute Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Synergy1	University of Alberta	Canadian Institutes of Health Research (CIHR);Crohn's and Colitis Canada;Beneo GmbH	Completed	18 Years	65 Years	All	24	N/A	Canada
63	NCT00403923 (ClinicalTrials.gov)	April 2007	24/11/2006	Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative Colitis	A Study to Determine the Threshold of Lactose Ingestion That Provokes Symptoms in Lactose Intolerant People Who Also Have Ulcerative Colitis	Lactose Intolerance;Ulcerative Colitis	Dietary Supplement: Lactose in water	University Hospitals, Leicester	NULL	Completed	18 Years	N/A	Both	48		United Kingdom
64	NCT00951548 (ClinicalTrials.gov)	October 2006	2/8/2009	Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis	Food Supplementation With the Probiotic Preparation VSL#3 as a Support to Standard Pharmaceutical Therapy in Patients With Mild to Moderate Active Ulcerative Colitis. A Double-blind, Randomized, Placebo Controlled Study	Ulcerative Colitis	Dietary Supplement: VSL#3;Dietary Supplement: Placebo	VSL Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	144	N/A	Italy
65	NCT00145015 (ClinicalTrials.gov)	December 2004	1/9/2005	FishGastro Study: Fish Consumption and Gastro-Intestinal Health	Fish Consumption and Gastro-Intestinal Health With Special Emphasis on Reduction of Risk of Colon Cancer and Inflammatory Bowel Disease	Colorectal Cancer;Ulcerative Colitis;Polyps	Behavioral: Increased dietary intake of salmon or cod	Institute of Food Research	Wageningen University;University of Jena;University of East Anglia;European Commission;Food Standards Agency, United Kingdom	Completed	18 Years	80 Years	Both	270	N/A	Netherlands;United Kingdom
66	EUCTR2004-000611-25-IE (EUCTR)	19/10/2004	16/08/2004	A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - CORE	A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - CORE	Maintenance of remission of ulcerative colitis	Product Name: OPC-6535 Product Code: OPC-6535 Other descriptive name: 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid Trade Name: Asacol (mesalamine) Delayed-release Tablets Product Name: Asacol INN or Proposed INN: Mesalamine Other descriptive name: 5-amino-2-hydroxybenzoic acid	Otsuka Maryland Research Institute, Inc.	NULL	Not Recruiting			Female: yes Male: yes	1725	Phase 3	Hungary;Ireland
67	EUCTR2004-000611-25-HU (EUCTR)	15/10/2004	21/07/2004	A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - CORE	A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - CORE	Maintenance of remission of ulcerative colitis	Product Name: OPC-6535 Product Code: OPC-6535 Other descriptive name: 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid Trade Name: Asacol (mesalamine) Delayed-release Tablets Product Name: Asacol INN or Proposed INN: Mesalamine Other descriptive name: 5-amino-2-hydroxybenzoic acid	Otsuka Maryland Research Institute, Inc.	NULL	Not Recruiting			Female: yes Male: yes	1725	Phase 3	Hungary;Ireland
68	NCT00259558 (ClinicalTrials.gov)	April 2003	25/11/2005	Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis	Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa	Ulcerative Colitis	Drug: retarded release phosphatidylcholine	Heidelberg University	Prof. Wolfgang Stremmel;Dietmar Hopp Stiftung	Completed	16 Years	90 Years	Both	60	Phase 2	Germany
69	NCT00259571 (ClinicalTrials.gov)	April 2003	28/11/2005	Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.	Prospektive, Randomisierte, Doppelblinde, Mesalazin-kontrollierte (Double-dummy Verfahren) Multizenter-Studie Zur Beurteilung Der Annahme Der äquivalenten Wirkung Von Intestinal Retardiert Freigesetztem Phosphatidylcholin gegenüber Mesalazin (Non-inferiority Study) in Der Remissionserhaltung Der Colitis Ulcerosa.	Ulcerative Colitis	Drug: retarded release phosphatidylcholine	Heidelberg University	Dietmar Hopp Stiftung	Withdrawn	15 Years	80 Years	Both	0	Phase 2/Phase 3	Germany
70	NCT00259545 (ClinicalTrials.gov)	February 2003	25/11/2005	Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis	Prospektive, Randomisierte Doppelblinde Studie Zur Wirksamkeit Von Intestinal Retardiert Freigesetztem Phosphatidylcholine Bei therapierefraktärer Colitis Ulcerosa Mit Chronisch Aktivem Verlauf Unter Corticosteroiden	Ulcerative Colitis;Phosphatidylcholine	Drug: Retarded Release Phosphatidylcholine (rPC)	Heidelberg University	Professor Wolfgang Stremmel;Dietmar Hopp Stiftung	Completed	16 Years	90 Years	Both	60	Phase 2	Germany
71	NCT00940576 (ClinicalTrials.gov)	July 2000	15/7/2009	Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases	Dietetic Effects of Mare's Milk in Patients With Chronic Inflammatory Bowel Diseases (IBD) - a Double Blind Placebo Controlled Cross-over Study.	Ulcerative Colitis;Crohns Disease	Dietary Supplement: mare´s milk;Other: placebo drink	University of Jena	German Federal Ministry of Education and Research	Completed	10 Years	50 Years	All	17	N/A	Germany

Back to top

240. Phenylketonuria

---

Clinical trials : 138 /  Drugs : 106 - (DrugBank : 11) / Drug target gene : 1 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05096988 (ClinicalTrials.gov)	November 23, 2021	14/10/2021	A Study to Evaluate the Acceptability, Tolerance and Adherence of Children and Adults Consuming PKU Sphere Liquid, a Food for Special Medical Purposes (FSMP), for the Dietary Management of Phenylketonuria (PKU)	A Study to Evaluate the Acceptability, Tolerance and Adherence of Children and Adults Consuming PKU Sphere Liquid, a Food for Special Medical Purposes (FSMP), for the Dietary Management of Phenylketonuria (PKU)	Phenylketonurias	Dietary Supplement: PKU sphere liquid	Vitaflo International, Ltd	NULL	Recruiting	3 Years	N/A	All	15	N/A	United Kingdom
2	NCT04898829 (ClinicalTrials.gov)	September 3, 2021	11/5/2021	Evaluation of PKU Explore France	An Exploratory Study to Evaluate the Acceptability of PKU Explore, a Food for Special Medical Purposes, for Use in the Dietary Management of Phenylketonuria in Infants From 6 Months to 3 Years of Age With Regard to Product-acceptability, Tolerance, Phe Levels and Growth	Phenylketonurias	Dietary Supplement: PKU explore	Vitaflo International, Ltd	NULL	Recruiting	6 Months	3 Years	All	10	N/A	France
3	NCT05051657 (ClinicalTrials.gov)	June 14, 2021	10/9/2021	Evaluation of PKU Express Plus	A Study To Evaluate The Acceptability Of PKU Express Plus, A Food For Special Medical Purposes (FSMP), In Children And Adults With Phenylketonuria (PKU)	Phenylketonurias;PKU	Dietary Supplement: PKU express plus	Vitaflo International, Ltd	NULL	Recruiting	3 Years	N/A	All	15	N/A	United Kingdom
4	NCT04375592 (ClinicalTrials.gov)	February 1, 2021	21/4/2020	Acceptability and Tolerance of a Ready-to-use Protein Substitute in Tablet Form for the Dietary Management of Phenylketonuria	XPhe Minis - Acceptability and Tolerance Market Research	Phenylketonurias;Hyperphenylalaninaemia;Tetrahydrobiopterin Deficiency	Dietary Supplement: Phenylalanine-free protein substitute in tablet form (XPhe minis)	metaX Institut fuer Diatetik GmbH	Birmingham Children's Hospital	Recruiting	7 Years	18 Years	All	10		United Kingdom
5	NCT05062226 (ClinicalTrials.gov)	September 16, 2020	6/9/2021	GMP Case Studies of Tolerance, Safety and Acceptability in PKU and TYR	Evaluating the Tolerance, Safety and Acceptability of GMP-based Protein Substitutes for the Dietary Management of Phenylketonuria and Tyrosinaemia in Children and Adults: a Case Study Series	PKU;Tyrosinemias	Dietary Supplement: PKU/TYR GMP Protein Substitute	Nutricia UK Ltd	NULL	Recruiting	3 Years	N/A	All	45	N/A	United Kingdom
6	NCT04272736 (ClinicalTrials.gov)	September 1, 2020	29/8/2018	PKU Low Calorie Drink Study	Evaluating the Compliance, Acceptability, Safety and Tolerance of a Lower Calorie Protein Substitute for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot Study	Phenylketonurias;Hyperphenylalaninaemia	Dietary Supplement: Low calorie protein substitute	Nutricia UK Ltd	NULL	Not yet recruiting	3 Years	N/A	All	30	N/A	NULL
7	NCT04302194 (ClinicalTrials.gov)	May 1, 2020	7/3/2020	Early Dietary Treated Patients With Phenylketonuria Can Achieve Normal Growth and Mental Development.	Early Dietary Treated Patients With Phenylketonuria Can Achieve Normal Growth and Mental Development.	Phenylketonurias	Dietary Supplement: phenylalanine restricted diet	Assiut University	NULL	Not yet recruiting	1 Month	3 Years	All	50		NULL
8	NCT04679467 (ClinicalTrials.gov)	January 15, 2020	26/11/2020	Evaluation of PKU Sphere in Italy	An Acceptability Study to Evaluate the Tolerance, Adherence and Metabolic Control of Patients With Phenylketonuria (PKU) Consuming PKU Sphere™, a Glycomacropeptide (GMP) Based Protein Substitute, When Introduced According to a Practical Guide to PKU Sphere.	Phenylketonurias;PKU	Dietary Supplement: PKU sphere	Vitaflo International, Ltd	NULL	Recruiting	3 Years	N/A	All	20	N/A	Italy
9	NCT04404530 (ClinicalTrials.gov)	October 8, 2019	21/5/2020	Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)	Palynziq and PKU: Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status, and the Metabolome	Phenylketonurias	Drug: Palynziq	Emory University	BioMarin Pharmaceutical	Recruiting	16 Years	N/A	All	45		United States
10	NCT03924180 (ClinicalTrials.gov)	September 19, 2019	22/4/2019	Glytactin EfficiEncy in Non or Insufficiently Treated Adult PHENylketonuria Patients	Glytactin EfficiEncy in Non or Insufficiently Treated Adult PHENylketonuria Patients	Adult Phenylketonuria Non Treated Patients	Dietary Supplement: Dietary Supplement for PKU patients	University Hospital, Tours	INSERM CIC 1415	Recruiting	18 Years	N/A	All	32	N/A	France
11	NCT03788343 (ClinicalTrials.gov)	August 19, 2019	17/12/2018	Phenylalanine and Its Impact on Cognition	PICO: Phenylalanine and Its Impact on Cognition - Impact of Phenylalanine on Cognitive, Cerebral and Neurometabolic Parameters in Adult Patients With Phenylketonuria	Phenylketonuria	Dietary Supplement: Phenylalanine;Drug: Placebo	University Hospital Inselspital, Berne	University of Zurich	Recruiting	18 Years	N/A	All	60	Phase 4	Switzerland
12	NCT04224142 (ClinicalTrials.gov)	July 29, 2019	7/10/2019	Evaluation of PKU Sphere in Maternal PKU	An Observational Study to Evaluate Metabolic Control and Dietary Management in Women With PKU Taking PKU Sphere During Pre-conception and/or Pregnancy	Maternal Phenylketonuria	Dietary Supplement: PKU sphere	Vitaflo International, Ltd	University College London Hospitals	Recruiting	16 Years	N/A	Female	10		United Kingdom
13	NCT03939052 (ClinicalTrials.gov)	July 19, 2019	1/5/2019	Protein Requirements in Adults With Phenylketonuria (PKU)	Protein Requirements in Phenylketonuria (PKU) Patients Compared Using PKU Sphere™ | Glycomacropeptide (GMP) and an L-amino Acid-based Product	Phenylketonuria	Dietary Supplement: Free amino acids intake	University of British Columbia	Vitaflo International, Ltd	Recruiting	19 Years	50 Years	All	6	N/A	Canada
14	NCT03333720 (ClinicalTrials.gov)	July 15, 2019	18/9/2017	Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria	Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria	Phenylketonurias	Dietary Supplement: Phenylalanine-free protein substitute tablets	Nutricia UK Ltd	NULL	Withdrawn	8 Years	100 Years	All	0	N/A	NULL
15	NCT03820804 (ClinicalTrials.gov)	January 7, 2019	19/10/2018	Nutritional Status in Phenylketonuria	Trends in Nutritional Status of Patients With Phenylketonuria	Phenylketonurias	Other: Diet;Drug: Sapropterin	Universidade do Porto	Centro Hospitalar do Porto;BioMarin Pharmaceutical	Completed	3 Years	N/A	All	94		Portugal
16	NCT03771391 (ClinicalTrials.gov)	December 6, 2018	7/12/2018	Multicentre Study Project to Evaluate the New Generation of Protein Supplements With Glycomacropeptide (GMP) in Patients With Phenylketonuria (PKU) Aged 10 Years and Older Over a 16 Week Period.	Multicentre Study Project to Evaluate the New Generation of Protein Supplements With Glycomacropeptide (GMP) in Patients With Phenylketonuria (PKU) Aged 10 Years and Older Over a 16 Week Period.	Phenylketonurias	Dietary Supplement: PKU Sphere	Vitaflo International, Ltd	Kreiskliniken Reutlingen;Johannes Gutenberg University Mainz	Active, not recruiting	10 Years	N/A	All	15	N/A	Germany
17	NCT03419819 (ClinicalTrials.gov)	May 1, 2018	3/1/2018	Evaluation of PKU Sphere	Evaluation of the Acceptability, Tolerance, and Satiety of PKU Sphere, a Glycomacropeptide (GMP) Based Medical Food in Patients With Phenylketonuria (PKU).	Phenylketonurias	Dietary Supplement: PKU Sphere	Vitaflo International, Ltd	Oregon Health and Science University	Completed	3 Years	N/A	All	28	N/A	United States
18	NCT02677870 (ClinicalTrials.gov)	January 2018	26/1/2016	The Effectiveness of Kuvan in Amish PKU Patients	The Effectiveness of High-Dose Synthetic BH4 (Saproterin Dihydrochloride or Kuvan) in Amish PKU Patients	Phenylketonuria	Drug: saproterin dihydrochloride;Other: Diet treatment	University Hospitals Cleveland Medical Center	BioMarin Pharmaceutical	Recruiting	2 Years	60 Years	All	25	Phase 4	United States
19	NCT03168399 (ClinicalTrials.gov)	June 8, 2017	24/5/2017	Evaluation of PKU Explore	A Study to Evaluate the Acceptability of PKU Explore, a Renovated Phenylalanine Free Second Stage Protein Substitute for Use in the Dietary Management of Phenylketonuria in Infants From 6 Months to 5 Years of Age With Regard to Product Tolerance and Adherence.	Phenylketonuria;Inborn Errors of Metabolism	Dietary Supplement: PKU Explore	Vitaflo International, Ltd	Birmingham Women's and Children's NHS Foundation Trust	Completed	6 Months	5 Years	All	22	N/A	United Kingdom
20	NCT03167697 (ClinicalTrials.gov)	May 1, 2017	22/5/2017	Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia	Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia	Phenylketonurias;Hyperphenylalaninaemia, Type I	Dietary Supplement: Synergy;Other: Routine	Nutricia UK Ltd	NULL	Completed	16 Years	100 Years	All	14	N/A	United Kingdom
21	NCT03058848 (ClinicalTrials.gov)	March 6, 2017	16/2/2017	Evaluation of PKU Start	A Study to Evaluate the Acceptability of a New Phenylalanine Free Infant Formula for Use in the Dietary Management of Phenylketonuria in Infants From Birth to 2 Year of Age With Regard to Product Tolerance and Adherence.	Phenylketonuria;Inborn Errors of Metabolism	Dietary Supplement: PKU Start	Vitaflo International, Ltd	NULL	Completed	N/A	2 Years	All	10	N/A	United Kingdom
22	NCT02915510 (ClinicalTrials.gov)	July 2016	8/8/2016	GMP Drink for PKU Study	Evaluating the Tolerance, Safety and Acceptability of PKU GMPro, a Whey Protein Derived Feed for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot Trial	Phenylketonuria	Dietary Supplement: Glycomacropeptide-based protein substitute	Nutricia UK Ltd	NULL	Completed	3 Years	N/A	All	40	N/A	United Kingdom
23	NCT02440932 (ClinicalTrials.gov)	November 2014	30/4/2015	Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis	Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis	Phenylketonuria (PKU)	Dietary Supplement: Phenylketonuria-type diet;Other: Normal (control) diet	University of Glasgow	NULL	Completed	18 Years	45 Years	Both	26	N/A	United Kingdom
24	EUCTR2010-021343-41-NL (EUCTR)	21/03/2014	30/11/2011	Variations of blood phenylalanine and tyrosine in children with phenylketonuria under sapropterin	Effect of sapropterin on variations of blood phenylalanine and tyrosine over 24 hours and from day to day in children with phenylketonuria	Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder by a mutation in the gene for the enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. Left untreated, the disease will result in high concentrations of phenylalanine (Phe) in blood and tissues, likely resulting in severe mental retardation and behavioural problems. Treatment focusus on the restriction of dietary phenylalanine intake with supplementation of a synthetic phenylalaninefree amino acid mixture.;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Kuvan	University Medical Center Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Netherlands
25	NCT01965691 (ClinicalTrials.gov)	October 2013	16/10/2013	Protein Requirements in Children With Phenylketonuria (PKU)	Application of Stable Isotopes to Determine Protein Requirements in Children With Phenylketonuria (PKU)	Phenylketonuria	Dietary Supplement: Protein intake	University of British Columbia	Rare Disease Foundation, Vancouver, Canada;Saudi Arabian Cultural Bureau, Ottawa	Completed	5 Years	18 Years	All	4	N/A	Canada
26	NCT01617070 (ClinicalTrials.gov)	May 2012	8/6/2012	Effects of Kuvan on Melatonin Secretion	Pilot Study to Evaluate Melatonin Secretion as a Marker of Decreased Serotonin in Individuals With PKU: Evaluation of the CNS Effects of Tetrahydrobiopterin	Phenylketonuria (PKU)	Drug: Kuvan;Dietary Supplement: Large Neutral Amino Acid Therapy	University of Southern California	BioMarin Pharmaceutical	Completed	18 Years	N/A	All	10	Phase 4	United States
27	NCT01376908 (ClinicalTrials.gov)	June 2011	17/6/2011	Kuvan® in Phenylketonuria Patients Less Than 4 Years Old	A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patients <4 Years Old.	Phenylketonuria	Drug: Kuvan®;Other: Phenylalanine (Phe)-restricted diet	BioMarin Pharmaceutical	NULL	Completed	N/A	4 Years	All	56	Phase 3	Austria;Belgium;Czechia;Germany;Italy;Netherlands;Slovakia;Turkey;United Kingdom;Czech Republic;Portugal
28	NCT01412437 (ClinicalTrials.gov)	April 2011	1/8/2011	Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria	Multimodal Neuroimaging and Neurocognitive Assessment of Biomarkers and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria	PKU	Dietary Supplement: diet;Drug: sapropterin dihydrochloride	Children's Research Institute	Georgetown University	Withdrawn	18 Years	40 Years	Both	0	N/A	United States
29	NCT00909012 (ClinicalTrials.gov)	May 2009	22/4/2009	Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria	Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria	Phenylketonuria	Dietary Supplement: high oleic sunflower oil;Dietary Supplement: microalgal oil	Ludwig-Maximilians - University of Munich	European Union	Completed	5 Years	13 Years	All	114	N/A	Germany;Italy;Spain;United Kingdom
30	NCT00841100 (ClinicalTrials.gov)	December 2008	10/2/2009	Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response	Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response	Phenylketonuria	Drug: Kuvan;Other: Diet	University of Miami	NULL	Completed	4 Years	N/A	All	21	Phase 2	United States
31	NCT00892554 (ClinicalTrials.gov)	June 2007	1/5/2009	The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)	The Impact of Docosahexaenoic Acid on Neuropsychological Status in Females With Phenylketonuria	Phenylketonuria	Dietary Supplement: Docosahexaenoic Acid;Dietary Supplement: Corn/soy oil	Emory University	Atlanta Clinical and Translational Science Institute	Completed	12 Years	50 Years	Female	33	N/A	United States
32	EUCTR2005-003777-24-GB (EUCTR)	17/08/2006	20/04/2006	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NA	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NA	Phenylketonuria (PKU) MedDRA version: 6.1;Classification code 10034872	Product Name: Phenoptin Product Code: T1401 INN or Proposed INN: Sapropterin Other descriptive name: sapropterin dihydrochloride	BioMarin Pharmaceutical Inc.	NULL	Not Recruiting			Female: yes Male: yes	300	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Spain;Germany;United Kingdom
33	EUCTR2005-003777-24-DE (EUCTR)	24/03/2006	14/12/2005	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NA	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NA	Phenylketonuria (PKU) MedDRA version: 6.1;Classification code 10034872	Product Name: Phenoptin Product Code: T1401 INN or Proposed INN: Sapropterin Other descriptive name: sapropterin dihydrochloride	BioMarin Pharmaceutical Inc.	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	Germany;Spain
34	EUCTR2005-003777-24-ES (EUCTR)	01/03/2006	19/01/2006	Estudio fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de PhenoptinTM en dosis de 20 mg/kg/dia para aumentar la tolerancia a la fenilalanina en niños fenilcetonúricos que siguen dietas restrictivas en fenilalanina.	Estudio fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de PhenoptinTM en dosis de 20 mg/kg/dia para aumentar la tolerancia a la fenilalanina en niños fenilcetonúricos que siguen dietas restrictivas en fenilalanina.	Fenilcetonuria (Phenylketonuria-PKU) MedDRA version: 6.1;Classification code 10034872	Product Name: Phenoptin Product Code: T1401 INN or Proposed INN: Sapropterin Other descriptive name: Sapropterin dihydrochloride	BioMarin Pharmaceutical Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300		Germany;Spain
35	EUCTR2004-002365-21-DK (EUCTR)	03/11/2004	09/07/2008	Trial with BH4, a new and simple treatment of phenylketonuria, PKU - BH4 and PKU	Trial with BH4, a new and simple treatment of phenylketonuria, PKU - BH4 and PKU	PKU, phenylketonuria, is a rare, inherited metabolic disease that results in mental retardation if not a very strict low-protein diet is started within the first weeks of life. The conversion of phenylalanine to tyrosine is defect, phe accumulates and leads to brain damage. There are different degrees of severity, reflecting the spectrum of mutant genes. BH4, tetrahydrobiopterin, is co-enzym for the conversion of phe to tyrosine. BH4 can lower phe in some patients with milder forms of PKU.	Product Name: tetrahydrobiopterin	John F. Kennedy Institute	NULL	Not Recruiting			Female: yes Male: yes			Denmark
36	NCT00065299 (ClinicalTrials.gov)	May 1984	21/7/2003	Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)	Effects of Maternal Phenylketonuria (PKU) on Pregnancy Outcome	Phenylketonuria	Behavioral: Restricted phenylalanine diet	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Completed	N/A	N/A	Female	572	N/A	United States
37	NCT00006142 (ClinicalTrials.gov)	December 1983	3/8/2000	Study of a Phenylalanine Restricted Diet During Pregnancy to Prevent Symptoms in Offspring of Patients With Phenylketonuria		Phenylketonuria	Behavioral: phenylalanine restricted diet	National Center for Research Resources (NCRR)	University of Texas	Completed	N/A	N/A	Female		N/A	NULL

Back to top

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03931252 (ClinicalTrials.gov)	January 2022	25/4/2019	Thermic Effect of Feeding in Cystic Fibrosis	Thermic Effect of Feeding in Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Boost VHC;Dietary Supplement: Ensure High Protein	Virginia Commonwealth University	NULL	Enrolling by invitation	18 Years	N/A	All	10	N/A	United States
2	NCT04938726 (ClinicalTrials.gov)	November 1, 2021	9/6/2021	Ketone Supplementation in Cystic Fibrosis	Ketone Monoester Supplementation in Cystic Fibrosis: A Pilot and Feasibility Study	Cystic Fibrosis	Dietary Supplement: Ketone Monoester	University of Alabama at Birmingham	NULL	Not yet recruiting	18 Years	89 Years	All	25	N/A	NULL
3	NCT04531410 (ClinicalTrials.gov)	July 1, 2021	18/8/2020	NETwork of Linoleic Acid Supplementation in Cystic Fibrosis	Double-blind Randomized Controlled Study of Linoleic Acid Supplementation for 1 Year in Patients With Cystic Fibrosis - Influence on Clinical Status and Metabolism	Cystic Fibrosis	Dietary Supplement: linoleic acid supplementation;Dietary Supplement: oleic acid supplementation	Karolinska Institutet	European Society of Pediatric Gastroenterology, Hepatology and Nutrition	Enrolling by invitation	5 Years	15 Years	All	90	N/A	Italy;Norway;Poland;Sweden
4	NCT04496921 (ClinicalTrials.gov)	August 10, 2020	21/7/2020	Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis	Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis : A Pilot Study	Cystic Fibrosis	Dietary Supplement: Vitamin K supplementation, dose #1;Dietary Supplement: Vitamin K supplementation, dose #2	Institut de Recherches Cliniques de Montreal	Université de Montréal	Withdrawn	18 Years	N/A	All	0	N/A	Canada
5	NCT04166396 (ClinicalTrials.gov)	February 17, 2020	14/11/2019	Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis	Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Resveratrol;Dietary Supplement: NR;Dietary Supplement: Placebo	Virginia Commonwealth University	NULL	Recruiting	18 Years	N/A	All	36	N/A	United States
6	NCT04058340 (ClinicalTrials.gov)	July 30, 2019	12/8/2019	Taste Receptors Regulation in CF Patients	The Effects of Taste Receptors Regulation in Upper Airway Innate Immunity of CF Patients	Cystic Fibrosis	Dietary Supplement: lactizole nebulization;Other: Placebo	Medical Universtity of Lodz	NULL	Recruiting	6 Years	N/A	All	30	N/A	Poland
7	NCT03734744 (ClinicalTrials.gov)	June 17, 2019	6/11/2018	PK/PD of Vitamin D3 in Adults With CF	A Pilot Study Evaluating Single, High-dose Pharmacokinetics/Pharmacodynamics of Vitamin D3 in CF	Vitamin D Deficiency;Cystic Fibrosis	Dietary Supplement: Vitamin D3	University of Southern California	NULL	Suspended	18 Years	N/A	All	12	N/A	United States
8	NCT03710538 (ClinicalTrials.gov)	April 1, 2019	20/6/2018	The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis	The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Snack beverage;Behavioral: Exercise	Institut de Recherches Cliniques de Montreal	NULL	Recruiting	18 Years	N/A	All	14	N/A	Canada
9	NCT04966897 (ClinicalTrials.gov)	August 31, 2018	8/7/2021	Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis	Randomized, Double-blind, Cross-over Trial Assessing a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis	Cystic Fibrosis;Exocrine Pancreatic Insufficiency	Dietary Supplement: GlycosBio Nutritional Supplement + PERT placebo;Dietary Supplement: Standard Nutritional Supplement + PERT	GlycosBio, Inc.	Baylor College of Medicine	Completed	12 Years	N/A	All	10	N/A	United States
10	NCT03462056 (ClinicalTrials.gov)	May 17, 2018	5/3/2018	Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis	Pilot Study of Ready to Use Therapeutic Food to Promote Weight Gain in Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Cystic Fibrosis Ready to Use Supplemental Food	Washington University School of Medicine	Cystic Fibrosis Foundation	Completed	2 Years	12 Years	All	16	Phase 1/Phase 2	United States
11	NCT03205904 (ClinicalTrials.gov)	December 12, 2016	15/6/2017	Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.	Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.	Cystic Fibrosis-related Diabetes;Cystic Fibrosis	Dietary Supplement: Diet	Hospital de Clinicas de Porto Alegre	NULL	Completed	10 Years	N/A	All	20	N/A	Brazil
12	NCT02810691 (ClinicalTrials.gov)	July 2016	14/6/2016	The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis	The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis	Cystic Fibrosis-related Diabetes;Cystic Fibrosis	Dietary Supplement: Soluble fiber supplementation;Dietary Supplement: Placebo (for fiber supplementation)	Institut de Recherches Cliniques de Montreal	Canadian Cystic Fibrosis Foundation;Université de Montréal	Completed	18 Years	N/A	All	14	N/A	Canada
13	NCT02646995 (ClinicalTrials.gov)	January 2016	22/12/2015	Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients		Cystic Fibrosis	Dietary Supplement: modified lipid formulation;Dietary Supplement: Fish oil	Nestlé	NULL	Completed	5 Years	18 Years	All	16	N/A	Switzerland
14	NCT02589444 (ClinicalTrials.gov)	December 2015	20/10/2015	Vitamin D and Microbiota in Cystic Fibrosis	Pilot Study Evaluating the Role of Vitamin D Repletion on Gut and Lung Microbiota in Cystic Fibrosis	Vitamin D Deficiency;Cystic Fibrosis	Dietary Supplement: High-Dose Vitamin D3;Other: Stool Sample;Other: Sputum Sample;Other: Sham Comparator;Procedure: Blood draw	Emory University	NULL	Completed	18 Years	N/A	All	41	N/A	United States
15	NCT02518672 (ClinicalTrials.gov)	October 2015	3/8/2015	Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)	Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.	Cystic Fibrosis	Dietary Supplement: MAG-DHA;Dietary Supplement: Placebo	SCF Pharma	Centre de recherche du Centre hospitalier universitaire de Sherbrooke;Solutex (Spain)	Terminated	18 Years	N/A	All	11	Phase 2	Canada
16	NCT02690064 (ClinicalTrials.gov)	April 2015	19/2/2016	Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF	Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF	Cystic Fibrosis	Dietary Supplement: Acute Antioxidant;Dietary Supplement: Chronic Antioxidant;Other: Placebo	Augusta University	NULL	Recruiting	7 Years	N/A	All	80	N/A	United States
17	NCT02043717 (ClinicalTrials.gov)	January 2014	12/1/2014	Increased Vitamin D Reduces Pulmonary Exacerbations in CF	Increasing Vitamin D Serum Levels Reduces Pulmonary Exacerbations in Patients With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Vitamin D	Hadassah Medical Organization	NULL	Completed	4 Years	N/A	All	90	N/A	Israel
18	NCT00924547 (ClinicalTrials.gov)	November 2013	17/6/2009	Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis	Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma	Cystic Fibrosis	Dietary Supplement: Docosahexanoic Acid Supplement;Dietary Supplement: Placebo	Vanderbilt University	NULL	Completed	6 Years	N/A	Both	17	Phase 2	United States
19	NCT01880346 (ClinicalTrials.gov)	October 2013	12/6/2013	Comparison of Absorption of Vitamin D in Cystic Fibrosis	Vehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs Oil	Cystic Fibrosis	Dietary Supplement: Vitamin D Powder;Dietary Supplement: Vitamin D Oil	Emory University	NULL	Completed	18 Years	59 Years	Both	17	Phase 4	United States
20	NCT02048592 (ClinicalTrials.gov)	September 2013	16/12/2013	Impact of Immunonutrition on the Patients With Cystic Fibrosis	Impact of Immunonutrition on the Patients With Cystic Fibrosis	Cystic Fibrosis;Malnutrition;Oxidative Stress	Dietary Supplement: Impact-Nutridrink;Dietary Supplement: Nutridrink-Impact	University Hospital, Motol	NULL	Recruiting	18 Years	40 Years	Both	30	Phase 4	Czech Republic
21	NCT01859390 (ClinicalTrials.gov)	June 2013	17/5/2013	Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis	A Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Patients	Cystic Fibrosis	Drug: AquADEKs-2;Dietary Supplement: control multivitamin	University of Colorado, Denver	Cystic Fibrosis Foundation Therapeutics;Yasoo Health	Completed	10 Years	N/A	All	73	Phase 2	United States
22	NCT01837355 (ClinicalTrials.gov)	March 2013	10/4/2013	Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis	Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Rhamnosus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)	Pulmonary Inflammation;Cystic Fibrosis;Microbiota	Dietary Supplement: Lactobacillus rhamnosus;Dietary Supplement: Placebo	Cantonal Hospital of St. Gallen	Swiss Federal Institute of Technology;University Hospital Inselspital, Berne	Unknown status	6 Years	20 Years	All	68	N/A	Switzerland
23	NCT02014181 (ClinicalTrials.gov)	July 2012	27/11/2013	Flaxseed Modulates Inflammation and Oxidative Stress in CF	Flaxseed Modulates Oxidative Stress and Inflammatory Biomarkers in Stable Patients With Cystic Fibrosis and Healthy Controls	Cystic Fibrosis;Oxidative Stress;Inflammation	Dietary Supplement: finely ground flaxseed powder	University of Pennsylvania	NULL	Completed	18 Years	64 Years	Both	10	Phase 1	United States
24	NCT01417481 (ClinicalTrials.gov)	March 2012	15/8/2011	Effect of Glycine in Cystic Fibrosis	Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Glycine;Dietary Supplement: Placebo	Instituto Nacional de Enfermedades Respiratorias	Hospital Infantil de Mexico Federico Gomez;Instituto Mexicano del Seguro Social	Terminated	5 Years	15 Years	All	13	Phase 2	Mexico
25	NCT02128984 (ClinicalTrials.gov)	January 2012	28/3/2014	Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children	Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children	Cystic Fibrosis;Failure to Thrive;Malnutrition	Dietary Supplement: Symbiotic Formula with DHA and antioxidants;Dietary Supplement: Standard Formula	Laboratorios Ordesa	Quantum Experimental;Peruvian Clinical Research	Completed	1 Year	N/A	All	109	N/A	Peru;Spain
26	NCT00889434 (ClinicalTrials.gov)	November 1, 2011	20/4/2009	Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)	Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CF	Cystic Fibrosis	Dietary Supplement: ECGC;Dietary Supplement: Tocotrienol;Dietary Supplement: EGCG + Tocotrienol	Hadassah Medical Organization	NULL	Completed	18 Years	N/A	All	7	N/A	Israel
27	NCT01426256 (ClinicalTrials.gov)	October 2011	29/8/2011	Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)	Vitamin D for Enhancing the Immune System in Cystic Fibrosis	Cystic Fibrosis;Respiratory Tract Infections	Dietary Supplement: Cholecalciferol	Emory University	Cystic Fibrosis Foundation Therapeutics	Completed	16 Years	N/A	All	91	Phase 3	United States
28	NCT01783613 (ClinicalTrials.gov)	October 2011	31/1/2013	Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis	Study of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months;Dietary Supplement: Placebo: 50 mg/kg/day during 12 months	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	NULL	Completed	2 Months	100 Years	All	96	N/A	Spain
29	NCT01772758 (ClinicalTrials.gov)	August 2011	16/10/2012	Cystic Fibrosis and Endothelial Function: At Rest and During Exercise	Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise	Cystic Fibrosis	Drug: BH4 5mg;Drug: BH4 20mg;Dietary Supplement: Antioxidant Cocktail	Augusta University	NULL	Completed	7 Years	N/A	All	64	Phase 2	United States
30	NCT01315665 (ClinicalTrials.gov)	April 2011	14/3/2011	Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation	Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects	Cystic Fibrosis	Dietary Supplement: Broccoli sprouts	University Hospitals Cleveland Medical Center	Cystic Fibrosis Foundation	Completed	18 Years	49 Years	All	15	N/A	United States
31	NCT02029521 (ClinicalTrials.gov)	March 2011	30/12/2013	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth Failure	Cystic Fibrosis	Dietary Supplement: Oral reduced l-glutathione;Dietary Supplement: Placebo	Clark Bishop	NULL	Completed	18 Months	10 Years	All	47	N/A	Italy
32	NCT01494909 (ClinicalTrials.gov)	January 2011	15/12/2011	Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function	Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function	Cystic Fibrosis	Dietary Supplement: Ensure plus	Texas A&M University	Arkansas Children's Hospital Research Institute;University of Arkansas	Active, not recruiting	10 Years	N/A	All	31	N/A	United States
33	NCT01201434 (ClinicalTrials.gov)	October 2010	31/8/2010	Effect of Probiotics on Sputum Inflammation and Pulmonary Infections in Patients With Cystic Fibrosis	The Effect of Probiotics on Sputum Bacteria, Sputum Inflammation, and Pulmonary Infections in Patients With Cystic Fibrosis: A Double-blind Placebo-controlled Trial	Cystic Fibrosis	Dietary Supplement: Bio-25 probiotic	Sheba Medical Center	NULL	Terminated	5 Years	40 Years	Both	12	N/A	NULL
34	NCT01956916 (ClinicalTrials.gov)	October 2010	23/9/2013	Probiotics in Cystic Fibrosis	Effects of LGG Administration in Children With Cystic Fibrosis: A Randomized Controlled Trial	Cystic Fibrosis	Dietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placebo	Federico II University	NULL	Completed	2 Years	18 Years	Both	110	Phase 3	Italy
35	NCT01222273 (ClinicalTrials.gov)	September 2010	14/10/2010	Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis	Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis	Cystic Fibrosis;Allergic Bronchopulmonary Aspergillosis	Dietary Supplement: cholecalciferol (Vitamin D3)	University of Pittsburgh	National Heart, Lung, and Blood Institute (NHLBI)	Completed	12 Years	N/A	All	7	N/A	United States
36	NCT01321905 (ClinicalTrials.gov)	April 2010	23/3/2011	Prospective Intervention Study on Vitamin D in Patients With Cystic Fibrosis	5-month Pilot Intervention Study on Vitamin D in Patients With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Supplementation with vitamin D2/D3	Karolinska Institutet	Stockholm County Council, Sweden;Swedish Cystic Fibrosis Association	Recruiting	6 Years	N/A	Both	15	Phase 2	Sweden
37	NCT01051999 (ClinicalTrials.gov)	February 2010	15/1/2010	Glutamine Supplementation in Cystic Fibrosis	Glutamine Supplementation and Immunity in Adults With Cystic Fibrosis	Cystic Fibrosis;Immune Function	Dietary Supplement: Glutamine;Dietary Supplement: L-alanine	Emory University	Emmaus Medical, Inc.	Completed	18 Years	N/A	Both	17	Phase 2	United States
38	NCT01961661 (ClinicalTrials.gov)	September 2009	9/10/2013	Probiotics on Intestinal Inflammation in Cystic Fibrosis	Effect of Probiotics on Intestinal Inflammation and Microflora in Cystic Fibrosis: a Pilot Study	Cystic Fibrosis	Dietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placebo	Federico II University	NULL	Completed	2 Years	18 Years	Both	22	Phase 3	Italy
39	NCT01737983 (ClinicalTrials.gov)	May 2009	12/7/2012	Effect of Lactobacillus Reuteri in Cystic Fibrosis	Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.	CYSTIC FIBROSIS	Dietary Supplement: Lactobacillus reuteri;Dietary Supplement: placebo	Azienda Policlinico Umberto I	NULL	Completed	6 Years	42 Years	Both	61	Phase 4	Italy
40	NCT00685971 (ClinicalTrials.gov)	December 2008	27/5/2008	Cholecalciferol for Vitamin D in Adult Cystic Fibrosis (CF) Patients	Randomized Placebo-Controlled Trial of Cholecalciferol for Vitamin D Deficiency in Adults With Cystic Fibrosis	Cystic Fibrosis;Vitamin D Deficiency	Dietary Supplement: 5000 IU of cholecalciferol;Dietary Supplement: placebo	St. Michael's Hospital, Toronto	NULL	Completed	18 Years	N/A	Both	200	N/A	Canada
41	NCT00788138 (ClinicalTrials.gov)	October 2008	7/11/2008	Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis		Cystic Fibrosis	Dietary Supplement: Vitamin D3;Dietary Supplement: Placebo	Emory University	NULL	Completed	18 Years	70 Years	Both	30	N/A	United States
42	NCT00959010 (ClinicalTrials.gov)	October 2008	13/8/2009	Omega 3 Supplementation in Cystic Fibrosis Patients	Biochemical Effects of a Long-term Supplementation With Omega-3 Polyunsaturated Fatty Acids in Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: omega-3 triglycerides;Dietary Supplement: Placebo	Queen Fabiola Children's University Hospital	NULL	Completed	6 Years	60 Years	Both	15	Phase 3	Belgium
43	NCT01172301 (ClinicalTrials.gov)	July 2008	27/7/2010	Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis	Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Essential amino acid intake + Leucine vs total AA supplement	Texas A&M University	Arkansas Children's Hospital Research Institute	Completed	10 Years	21 Years	Both	14	N/A	United States
44	NCT00762918 (ClinicalTrials.gov)	March 2008	26/9/2008	Vitamin D3 for the Treatment of Low Vitamin D in Cystic Fibrosis	Vitamin D and Its Non-Classic Roles in Cystic Fibrosis	Cystic Fibrosis;Vitamin D Deficiency	Dietary Supplement: cholecalciferol	Children's Hospital of Philadelphia	NULL	Withdrawn	10 Years	25 Years	Both	0	Phase 3	United States
45	NCT01070446 (ClinicalTrials.gov)	October 2007	10/2/2010	Choline Nutrition in Children With Cystic Fibrosis	Choline Nutrition in Children With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1	University of British Columbia	Cystic Fibrosis Foundation (US)	Completed	5 Years	17 Years	Both	34	N/A	Canada
46	NCT01018303 (ClinicalTrials.gov)	August 2007	19/11/2009	Safety and Efficacy of an Antioxidant-rich Multivitamin Supplement in Cystic Fibrosis	Safety and Efficacy of a Novel Antioxidant-rich Multivitamin Supplement for Persons With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: AquADEK	University of Colorado, Denver	Cystic Fibrosis Foundation Therapeutics;Yasoo Health;National Institutes of Health (NIH)	Completed	10 Years	40 Years	Both	17	Phase 1/Phase 2	United States
47	NCT00406536 (ClinicalTrials.gov)	January 2007	29/11/2006	Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI	Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF	Cystic Fibrosis;Pancreatic Insufficiency	Dietary Supplement: Lym-X-Sorb powder;Dietary Supplement: Placebo powder	Avanti Polar Lipids, Inc.	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	6 Years	17 Years	Both	110	Phase 2	United States
48	NCT00730509 (ClinicalTrials.gov)	April 2004	4/8/2008	Effects of 5-Methyltetrahydrofolate and Vitamin B12 Supplemetation on Red Cell Membrane in Children With Cystic Fibrosis	Preliminary Evidences of Active Form of Folic Acid and Vitamin B12 Supplementation to Ameliorate Cell Membrane in Children With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: 5-methyltetrahydrofolate and vitamin B12	Universita di Verona	NULL	Completed	3 Years	8 Years	Both	31	N/A	Italy
49	NCT00530244 (ClinicalTrials.gov)	March 2003	13/9/2007	Use of Formula Fortified With DHA in Infants With Cystic Fibrosis	The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)	Cystic Fibrosis	Dietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)	University of Massachusetts, Worcester	Cystic Fibrosis Foundation	Completed	N/A	56 Days	All	76	N/A	United States

Back to top